Grabar Sophie, Costagliola Dominique
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP) and Assistance Publique-Hôpitaux de Paris (AP-HP), Unit of Public Health, St Antoine Hospital, 75001 Paris, France.
Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), INSERM, Sorbonne Université, 75001 Paris, France.
Cancers (Basel). 2021 Nov 14;13(22):5692. doi: 10.3390/cancers13225692.
Kaposi's sarcoma is an angioproliferative tumor caused by human herpesvirus 8 in the context of immunodeficiency, such as that induced by HIV infection or immunosuppressive therapy. Its incidence has dramatically fallen in patients living with HIV (PLHIV) since the introduction of potent antiretroviral combinations 25 years ago due to the restoration of immunity and better control of HIV replication. However, KS is still one of the most frequently occurring cancers in PLHIV, in particular in men who have sex with men and in sub-Saharan Africa, where it is still endemic. Even in the context of restored immunity, the risk of KS is still more than 30 times higher in PLHIV than in the general population. Recent evidence indicates that early initiation of antiretroviral treatment, which is recommended by current guidelines, may reduce the risk of KS but it needs to be accompanied by early access to care. This review mainly focuses on the recent epidemiological features of KS in the context of HIV infection.
卡波西肉瘤是一种血管增殖性肿瘤,由人类疱疹病毒8在免疫缺陷的情况下引起,例如由HIV感染或免疫抑制治疗所诱发。自25年前强效抗逆转录病毒联合疗法问世以来,由于免疫力的恢复以及对HIV复制的更好控制,HIV感染者(PLHIV)中卡波西肉瘤的发病率已大幅下降。然而,卡波西肉瘤仍是PLHIV中最常发生的癌症之一,尤其是在男男性行为者以及撒哈拉以南非洲地区,在那里它仍然是地方病。即使在免疫力恢复的情况下,PLHIV患卡波西肉瘤的风险仍比普通人群高出30多倍。最近的证据表明,按照现行指南建议尽早开始抗逆转录病毒治疗可能会降低患卡波西肉瘤的风险,但这需要同时尽早获得医疗护理。本综述主要关注HIV感染情况下卡波西肉瘤的近期流行病学特征。